A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity.
Functional analysis of androgen receptor (AR) gene mutations isolated from prostate cancer has led to the identification of residues that play important roles in the structure and function of the receptor. Here we report the characteristics of a novel AR mutation A748T located in helix 5 of the ligand-binding domain, which was identified in metastatic prostate cancer. Despite a normal hormone-binding affinity, A748T causes hormone concentration-dependent defects in nuclear accumulation and transcriptional activation. Moreover, when equivalent amounts of DNA are transfected, the mutant is expressed at much lower levels than the wild-type AR (ARWT). Treatment with geldanamycin to disrupt receptor-heat shock protein complexes rapidly decreases the levels of ARWT but not A748T, suggesting that the lower expression and rapid degradation rate of A748T is due to weaker interactions with heat shock proteins. Further analysis revealed that hormone dissociates from A748T five times faster than from ARWT. Loss of the ability to form stable amino/carboxyl-terminal interactions causes accelerated dissociation rates in some AR mutants. However, A748T exhibits normal amino/carboxyl-terminal interactions at high hormone concentrations, suggesting that the mutation alters interactions with ligand. Consistent with this conclusion, our structural model predicts that A748T disrupts crucial contact points with ligand, thereby altering the conformation of the ligand-binding domain.
James
Alaina J
AJ
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Agoulnik
Irina U
IU
Harris
Jonathan M
JM
Buchanan
Grant
G
Tilley
Wayne D
WD
Marcelli
Marco
M
Lamb
Dolores J
DJ
Weigel
Nancy L
NL
D000409:Alanine; D000818:Animals; D001665:Binding Sites; D001692:Biological Transport / Q000187:drug effects; D019556:COS Cells; D002467:Cell Nucleus / Q000378:metabolism; D013196:Dihydrotestosterone / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D015870:Gene Expression / Q000187:drug effects; D006360:Heat-Shock Proteins / Q000378:metabolism; D006801:Humans; D008297:Male; D015741:Metribolone / Q000008:administration & dosage / Q000494:pharmacology; D008958:Models, Molecular; D009154:Mutation; D011471:Prostatic Neoplasms / Q000235:genetics*; D011487:Protein Conformation; D011944:Receptors, Androgen / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*; D013329:Structure-Activity Relationship; D013739:Testosterone / Q000008:administration & dosage / Q000494:pharmacology; D013912:Threonine; D014158:Transcription, Genetic / Q000187:drug effects; D014162:Transfection
D006360:Heat-Shock Proteins; D011944:Receptors, Androgen; D013196:Dihydrotestosterone; D015741:Metribolone; D013912:Threonine; D013739:Testosterone; D000409:Alanine